The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://ncbi.nlm.nih.gov/pubmed/32039023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01550
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares